New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
ADDISON, Texas, April 19, 2007 /PRNewswire/ -- New clinical trial results for heart transplant patients will be released at the upcoming International Society for Heart and Lung Transplantation (ISHLT) 27th Annual Meeting and Scientific Sessions at the Hilton San Francisco, April 25-28, 2007. Results show promise for efficacy and safety of immunosuppression therapy and lower incidences of acute organ rejection in heart transplants.
Research to be presented includes: -- Six Month Data on Cyclosporine Reduction and Impact on Renal Function with Everolimus In De Novo Heart Transplant Recipients will be presented Wednesday, April 25 during a luncheon symposium at 12:30pm PDT. -- 6 Month Data from a 12 Month Study of Everolimus with Reduced Cyclosporine Exposure vs. MMF and Conventional Cyclosporine in De Novo Heart Transplant Recipients will be presented during the same luncheon symposium on April 25.
The leading cause of death during the first year following heart transplant is acute rejection of the transplanted organ. The patient's immune system attacks the heart as if it were a foreign object until it no longer functions properly. The one-year survival rate after transplantation is approximately 80 percent; this number drops to nearly 50 percent after 10 years.
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit organization dedicated to the advancement of the science and treatment of end-stage heart and lung diseases. Created in 1981, the Society now includes more than 2,200 members from 45-plus countries, representing a variety of disciplines involved in the management and treatment of end-stage heart and lung disease.
ISHLT manages two vital databases. The International Heart and Lung Registry is a one-of-a-kind registry that has been collecting data since 1983 from 223 hospitals from 18 countries. The ISHLT Mechanical Circulatory Device (MCSD) database has been collecting data since 2002 with the aim of identifying patient populations who may benefit from MCSD implantation, generating predictive models for outcomes; and assessing the mechanical and biological reliability of current and future devices. In Fall 2006, ISHLT released the first international guidelines for heart failure patient management. For more information, visit http://www.ishlt.org.
Contact: Lauren Mason
CONTACT: Lauren Mason, +1-210-731-6646, , forInternational Society for Heart and Lung Transplantation firstname.lastname@example.org
Web site: http://www.ishlt.org/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: April 2007